Background/Aims: 17β-estradiol (E2) is a risk factor for the development of breast cancer, and cause tumorigenesis in epithelial breast cells. Moreover, E2 has distinct effects on different tissues that are attributed to the presence of two estrogen receptor isoforms, ERα and ERβ. Methods: The effect of E2 on mitochondrial biogenesis and function was investigated in two breast cancer cell lines with different estrogen receptor ratios, MCF-7 (high ERα/ERβ ratio) and T47D (low ERα/ERβ ratio) cell lines treated with physiological concentrations of E2 (1 nM). Results: Mitochondria of the MCF-7 cell line showed an increase in proliferation but a decrease in functionality, while the T47D cell line, with low ERα/ERβ ratio, maintained functionality with fewer mitochondria. Conclusion: Our results suggest that ERs endowment and its subtypes relation have an effect on treatment response and could contribute new ideas about mitochondria and ERs in breast cancer, as well as new indicators to the disease progression.

Keywords:
Estrogen receptor alpha and beta ratio, Breast cancer, 17β-estradiol (E2), Mitochondrial biogenesis
This content is only available via PDF.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.